☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MTRAC Reviews - August 2013

MTRAC issued a new Commissioning Support review in August 2013. The review covers mirabegron.

The Mirabegron (Betmiga®) summary advises that this drug is suitable for prescribing in primary care. The committee considered the drug to have a lower place in therapy and relatively weak evidence due to limited comparative data with anti-muscarinics and limited long-term efficacy data. The committee also noted that NICE has recommended this treatment as an option for treating overactive bladder (OAB) only for people in whom anti-muscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects.

Action: Clinicians should be aware of these reviews and use the recommendations to guide appropriate use of these medicines in current practice.

Share 'MTRAC Reviews - August 2013' by emailShare 'MTRAC Reviews - August 2013' on FacebookShare 'MTRAC Reviews - August 2013' on TwitterShare 'MTRAC Reviews - August 2013' on LinkedInShare 'MTRAC Reviews - August 2013' on reddit

atomic-wealth

No Comments to “MTRAC Reviews - August 2013”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

governor
governor
governor
governor